Navigation Links
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
Date:6/26/2009

OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").

The Private Placement took place through a bookbuilding process and was managed by Carnegie ASA and DnB NOR Markets as joint-lead managers and joint bookrunners. The Private Placement, which represents approximately 80% of the current outstanding share capital, was well oversubscribed at the issue price and was supported by existing life science and institutional investors, including NeoMed Management and MVM Life Science Partners, as well as new institutional investors.

The net proceeds to the Company from the Private Placement will provide financial resources to achieve key clinical data on its products in development, and optimise its commercial strategy. More specifically, the Company intends to use the net proceeds to:

    i)  Obtain randomised data from clinical studies for lead products
         a. Complete first part of a Phase II/III registration study for
            elacytarabine in leukaemia (AML)
         b. Complete a randomised Phase II study with IV CP-4126 in
            pancreatic cancer
         c. Complete Phase I study for Oral CP-4126 in various solid cancers
    ii)  Achieve pre-clinical proof of concept for CP-4200
    iii) Place the company in a position of strength from which to negotiate
         appropriate partnership agreements as well as for general corporate
         purposes

Completion of the Private Placement is conditional upon approval by the Company's Extraordinary General Meeting to be held on or about 15 July 2009 (the "EGM"). Shareholders representing more than the required two thirds of the shares
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from ... three key industry events beginning with Patient-Centered Clinical Trials ... in Boston , September 4-5. Patient recruitment ... and Aaron Fleishman will share insights on the ... a variety of tactics – from media to mobile apps ...
(Date:8/28/2014)... new work by a Florida State University research team ... take your temperature, emit white light, and convert photon ... looks like a butterfly. , Biwu Ma, associate professor ... the FAMU-FSU College of Engineering, created the molecule in ... to discover that his creation has many other unique ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... 2014 Green & Grow Inc. (GGI) ... funding and secured Otter Capital as a significant new ... commercialization of GGI’s Agriplier™ technology, building on recent compelling ... “Since our first meeting, we have been impressed with ... space,” said Alan Sobba, President and CEO of GGI. ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Oct. 30 Prometheus Laboratories Inc., a,specialty ... U.S.,Patent and Trademark Office (USPTO) has issued ... Thiopurine Metabolites, a,diagnostic test that enables physicians ... and maintain desired therapeutic levels. The USPTO ...
... oncologist, discusses his breakthrough robotic surgery techniques, following an OR Live ... sexual function and continence. To date, Dr. Samadi has performed over ... his patients. , ... New York, NY (PRWEB) October ...
... Methylated DNA Quantification Kit significantly,simplifies the study of Global Methylation ... ... current methods, ST. LOUIS, Oct. ... Quantification Kit,(MDQ1) for epigenetic research http://www.sigma-aldrich.com/mdq1 . The,Methylated DNA ...
Cached Biology Technology:Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 3Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 4Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 2Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 3
(Date:8/31/2014)... at the University of Warwick have discovered that ,good, ... , The substance, methylglyoxal - MG, was found to ... bad cholesterol from the body. , Low levels ... heart disease, with increased levels of MG being common ... problems. , Supported by funding from the British ...
(Date:8/31/2014)... provides a fast and accurate tool to diagnose ... The newly developed test (TAM-TB assay) is the ... in children. The test features excellent specificity, a ... speed of a blood test. The promising findings ... tuberculosis in children, particularly in tuberculosis-endemic regions. , ...
(Date:8/31/2014)... the highly infectious bacteria C. diff , that ... by a team at the University of Leicester. , ... that it is possible to identify the unique ,smell, ... rapid diagnosis of the condition., What is more, the ... different strains of the disease simply from their smell ...
Breaking Biology News(10 mins):Sugar substance 'kills' good HDL cholesterol, new research finds 2New tuberculosis blood test in children is reliable and highly specific 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... the Gladstone Institutes and the Stanford University School of ... toxic buildup of a protein found in nerve cells. ... treating a variety of neurodegenerative conditions, including amyotrophic lateral ... which there is no cure. The Gladstone ...
... The ability of embryonic stem cells to differentiate into ... and maintained by a complex series of chemical interactions, ... process could prove useful for stem cell-based therapies down ... Carnegie,s Yixian Zheng zeroes in on the process by ...
... or mating or to capture bigger prey, but a University ... crab has a more self-serving social agenda: to kick another ... home., All hermit crabs appropriate abandoned snail shells for their ... crabs popular terrarium pets are the only ones ...
Cached Biology News:Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrig's disease 2Gladstone, Stanford scientists block toxic protein that plays key role in Lou Gehrig's disease 3Solving stem cell mysteries 2Hermit crabs socialize to evict their neighbors 2Hermit crabs socialize to evict their neighbors 3
... mitochondrial transmembrane potential is one ... that occur following induction of ... Kit utilizes a lipophilic cation, ... mitochondrial activity marker. MitoLight partitions ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
Biology Products: